Table 1.
F2-Isoprostane Levels in Asthma
| Study Design | F2-isoP Levels | Reactive oxygen species | Ref. |
|---|---|---|---|
| Adults: | [63] | ||
| 10 Healthy* | 15.8±1.6(pg/ml)a | eNO(ppb)b:6.5±0.6 | |
| 12 Mild Asthma* | 33.7±2.8 | 22.6±2.9 | |
| 17 Moderate* | 38.3±3.7 | 11.9±1.3 | |
| 15 Severe* | 49.1±5.0 | 10±1.8 | |
| Adults: | [29] | ||
| 9 Mild Atopic Asthma | |||
| Segmental allergen challenge | |||
| BAL-pre | 0.9±0.2 (pg/ml)c, d | ||
| 24h after | 11.4±3 | ||
| Urine-pre | 1.5±0.2 (ng/mg creat) | ||
| 2–8h after | 2.6±0.3 | ||
| Adults: | [25] | ||
| 38 Healthy# | 23.9 (17.2–48.9)g, e | eNO(ppb)b:15.9(12–21) | |
| 57 Asthma# | 46.9 (28.6–71.5) | 41.6(16.4–83.1) | |
| Children: | [64] | ||
| 15 Healthy+ | 139 (109–174)(pg/ml)e | ||
| 15 Asthma+ | 213 (122–455) | ||
| Children: | [65] | ||
| 12 Healthy* | 34.2±4.5 (pg/ml)f | PGE2(pg/ml)f:46.8±5.3 | |
| 12 Asthma/non-steroid* | 56.4±7.7 | 44.6±5.0 | |
| 30 Asthma/steroid-treated* | 47.2±2.3 | 51.5±4.0 | |
| Children: | LTC4/D4/E4e | [27] | |
| 10 Healthy* | 2.6 (2.1–3.0)(pg/ml)a,e | 4.3(2–5.7) | |
| 15 Asthma-Exacerbation* | 12.0 (9.4–29.5) | 12.7 (5.4–15.6) | |
| Post- prednisone* | 8.4 (5.4–11.6) | 5.2 (3.9–8.8) | |
| Children: | LTC4/D4/E4a | [33] | |
| 12 Asthma, + HDM* | 17.47±3.18 (pg/ml)a | 14.24±4.53 | |
| HDM avoidance, 3 months*. | 7.36±3.26 | 4.65±0.68 | |
| Children: | LTC4/D4/E4e | [66] | |
| 19 Healthy* | 3.5 (2.6–7.9) (pg/ml)e | 4.3 (2–8.3) | |
| 14 Asthma/ non-steroid* | 16.2 (11.7–19.1) | 10.8 (9.3–13.1) | |
| 13 ICS-treated Asthma* | 18.1 (14.8–20.5) | 12.7 (9.9–15.1) | |
| 9 Unstable Asthma* | 29.7 (4.8–35.1) | 106.0 (4.2–218) | |
| Children: | LTE4a,e | [67] | |
| 20 Healthy* | 15.5 (14.1–17.5)f,e | 12.5 (11.6–14.7) | |
| 20 Atopic/non-Asthma* | 15.8 (13.9–20.1) | 15.9 (12–17.5) | |
| 30 Atopic/Asthma* | 29.8 (26–34.3) | 28.2 (24.9–35.7) | |
| 25 Atopic/Asthma/ICS* | 33 (28.5–35.8) | 29 (25–36.6) | |
| Children: | [28] | ||
| 11 Healthy* | 3.8±0.6 (pg/ml)a | ||
| 13 Asthma/ non-steroid* | 9.3±1.7 | ||
| 12 ICS-treated Asthma* | 6.7±0.7 | ||
| Children: | [32] | ||
| Asthma | Pre-exercise (pg/ml)f | ||
| 34 non-EIB* | 32.3 (27.6–37) | ||
| 12 EIB* | 44.9 (38.3–51.5) | ||
a
EIA (Cayman Chemical);
b
Chemiluminescence analyzer;
c
Gas chromatography/negative-ion chemical ionization mass spectrometry (GC/NICI/MS);
d
No immediate release of F2-isoP into BAL after allergen challenge;
e
median and quartile range;
f
RIA;
g
2,3-dinor-8-epiPGF2α, a urinary metabolite of F2-isoP, determined by HPLC/NICI/MS.
Source of analysis:
*
EBC,
+
Plasma,
#
Urine.